It will therefore be interesting to follow the outcome of an ongoing randomized controlled trial addressing the effects of a single administration of single-dose of a humanized monoclonal antibody against the IL-6 receptor in patients with depression and serum concentrations of CRP ≥ 3 mg/L [113]. The gene discussed is CRP; the disease is depressive symptom measurement.